Navigation Links
Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
Date:3/8/2013

VANCOUVER, British Columbia, March 8, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CNSX: FLU) (OTC: ATTBF), is pleased to announce its participation in a research project led by Pamela Weathers , Professor of Biology and Biotechnology at Worcester Polytechnic Institute (WPI) in Worcester, Mass. that is investigating a whole plant therapeutic for treating malaria and other diseases, one that may also reduce drug resistance.

Mr. Mike Withrow , Chief Executive Officer on behalf of the Company, stated, "We are very excited to have the opportunity to explore a highly innovative approach to treat those diseases that are responsive to artemisinin. Our vertical hydroponic system and extraction methods could assist Professor Weathers' efforts in cultivating Artemisia annua for further developing this therapeutic technology."

Artemisinin, derived from the sweet wormwood plant, Artemisia annua, is an effective treatment for malaria, but it is expensive to produce (particularly when combined with other antimalarial medications to make it less prone to resistance) and is frequently in short supply. Research by the Weathers team has shown that powdered dried leaves from the plant may be a far more effective antimalarial treatment than purified artemisinin and may greatly reduce the risk of resistance.

"Working with Abattis provides an exciting opportunity to move this important medicinal plant into commercial utility for broader public use. I am looking forward to what I anticipate will be a very fruitful relationship," said Professor Weathers.

Professor Weathers received her Ph.D. at the Michigan State University Plant Research Lab in 1974. She has received numerous awards for her research and many international speaking invitations. She is a Fellow of the Society for In Vitro Biology. Her work on A. annua spans over 20 years and her team was the first to genetically transform the plant. She has several patents and about 100 peer-reviewed publications, of which more than a third are on A. annua or artemisinin. She has supervised many undergraduate and graduate student theses on many aspects of plant biotechnology including bioreactor development for in vitro plant propagation.

About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in Pharmaceutical, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.

About Worcester Polytechnic Institute
Founded in 1865 in Worcester, Mass., WPI was one of the nation's first engineering and technology universities. Its 14 academic departments offer more than 50 undergraduate and graduate degree programs in science, engineering, technology, business, the social sciences, and the humanities and arts, leading to bachelor's, master's and doctoral degrees. WPI's talented faculty work with students on interdisciplinary research that seeks solutions to important and socially relevant problems in fields as diverse as the life sciences and bioengineering, energy, information security, materials processing, and robotics. Students also have the opportunity to make a difference to communities and organizations around the world through the university's innovative Global Perspective Program. There are more than 30 WPI project centers throughout North America and Central America, Africa, Australia, Asia, and Europe.

ON BEHALF OF THE BOARD

" Michael Withrow "       
Michael Withrow , President & CEO

Neither the CNSX Exchange nor its regulations services accepts responsibility
for the adequacy or accuracy of this release.

Contact:
Mr. Mike Withrow
778-896-6536


'/>"/>
SOURCE Abattis Bioceuticals Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DATATRAK Participates in March Industry Events
2. Acceliant Participates as Platinum Sponsor at the SCDM Annual Conference in Los Angeles
3. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
4. PRA Participates in Landmark Alzheimers Prevention Clinical Trial
5. Misonix Participates In Cleveland Spine Review
6. BlackStratus participates in Joint FDA-ISPE CGMP Conference
7. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
8. Nutrastar International Completes Multi-Year Production Expansion Project Bringing Cordyceps Capacity to 100 Tons
9. CPhI in Partnership With PMI India Announces Pharma Project Management Conference
10. Physicians Capital Investments Receives "Outstanding Development Award" for Sandy, Oregon Project
11. Natalie Douglas, CEO of Idis, Joins Global Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest ... . , Millions of individuals in the United States and Canada wear eyeglasses. Once ... to both correct vision and make a fashion statement. Even celebrities use glasses as ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):